Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

Overseen By Monica Gruber

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Happify Inc.

Disqualifiers: Suicide risk, Substance use, PTSD, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 8-10 weeks

367 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a digital therapeutic program for adults with depression or anxiety. Participants use the program on their devices for a few months, completing activities and assessments to help manage their mental health.

Who Is on the Research Team?

Roger Vilardaga, Ph.D.

Principal Investigator

Duke University

Are You a Good Fit for This Trial?

Inclusion Criteria

You have a computer or smartphone that can be used for the study, and you are willing to use it throughout the study.

You currently live in the United States.

You have been diagnosed with Major Depressive Disorder or Generalized Anxiety Disorder according to the DSM-5 criteria.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants use the HPDT-DA-013 digital therapeutic for 8-10 weeks, completing PHQ-9 and GAD-7 assessments, as well as safety and medication use questionnaires

8-10 weeks

Follow-up

Participants are monitored monthly for safety and effectiveness after treatment

12 months

What Are the Treatments Tested in This Trial?

Interventions

• HPDT-DA-013

How Is the Trial Designed?

Group I: Digital therapeutic Experimental Treatment 1 Intervention

Use HPDT-DA-013 digital therapeutic for a period of 8-10 weeks.

Who Is Running the Clinical Trial?

Happify Inc.

Lead Sponsor

Trials

7

Recruited

21,600+